Clinical Trials | January 06, 2026
RedHill Biopharma advances RHB-102 as once-daily oral therapy to combat GLP-1 side effects
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
